Traditional Chinese Medicine to Take FDA's Test of Curative Effect By Synarc
Posted on: Thursday, 27 October 2005, 09:00 CDT
Traditional Chinese medicine to take FDA's test of curative effect by Synarc
BEIJING, Oct. 26 (Xinhua) -- A traditional Chinese medicine will undergo a clinical curative effect test given by Synarc in line with the US Food and Drug Administration(FDA)'s requirement.
Tongjitang Pharmaceutical Co. Ltd. of southwest China's Guizhou Province signed a contract with Synarc, a US professional drug test service provider, in Beijing on Tuesday. Synarc will carry out clinical curative effect test on a traditional Chinese medicine to treat osteoporosis.
It is for the first time a Chinese herbal medicine to be tested in line with western clinical curative effect standards, Qi Guomin, official of Ministry of Health, told Xinhua on Wednesday.
Some of the Chinese traditional medicines have passed the FDA's safety test and been sold as "health food" in western countries, Qi said.
Professor Luo Xianzheng of Chinese Medical Association said on the signing ceremony that one of the major obstacle making Chinese herbal medicine unacceptable to western countries and people is the traditional Chinese medicine does not have quantitative data of its effectiveness. China's export of herbal materials is much more than the herbal officinals, Luo said.
"To persuade westerners to use Chinese medicine, scientific and accurate test data are essential," Qi said.
Undergoing quantitative measurement and evaluation is the only way to introduce Chinese herbal drug to the world's pharmaceutical market, professor Luo said.
The test will be carried out in China under FDA's criteria and the result will be released in 2006.
Source: Xinhua News Agency - CEIS
Related Articles
- Frost & Sullivan Finds Attractive Investment Opportunities in Chinese Test & Measurement Market
- AspenBio Pharma Reports on FDA 510(K) Clinical Trial Progress for AppyScore, World's First Blood-Based Diagnostic Test for Human Appendicitis
- Guided Therapeutics, Inc. Announces Completion of Subject Enrollment of FDA Pivotal Clinical Trial
- Patient Enrollment for AspenBio Pharma's FDA 510(K) Clinical Trial for AppyScore(TM), World's First Appendicitis Blood Test, Nearing Halfway Point
- AstraZeneca's Statement on the Cost-Effectiveness Findings of the Clinical Antipsychotic Trials of Intervention Effectiveness-Schizophrenia (CATIE-SZ)
- Over Half of German Population Favor Combined Treatment of Chinese,Western Medicine
- Test Shows Vaccine Gardasil Effective Against Cervical Cancer
- Experts Say Integration of Chinese, Western Medicine to Prolong AIDS Patients' Lives
- Traditional Chinese Medicinal Capsule for Curing HIV/AID Undergoes Clinical Test
- China Health Holding Announces Pharmaceutical Development Plans Seeking FDA Approval for Promising Traditional Herbal Medicines
 |
 |
User Comments (0)
RSS Feeds